GTHX - G1セラピュ―ティクス （G1 Therapeutics Inc.） G1セラピュ―ティクスGTHXのチャート
GTHXの企業情報
| symbol | GTHx |
|---|---|
| 会社名 | G1 Therapeutics Inc （G1セラピュ―ティクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 G1セラピューティクス(G1 Therapeutics Inc.)は臨床段階のバイオ医薬品会社である。同社はがん治療用小分子療法の開発に従事する。同社の2つの臨床段階の候補はキナーゼ標的CDK4 / 6の選択的阻害剤であるトリラシクリブ（G1T28）およびG1T38である。トリラシクリブおよびG1T38は現在の治療法の抗腫瘍活性を増強するように設計される。同社はまた、乳癌の治療用経口選択的エストロゲン受容体分解酵素（SERD）であるG1T48を開発中である。3つの第II相臨床試験において、同社はトリラシクリブを評価する。G1T38はエストロゲン受容体陽性HER2陰性乳癌患者のフェーズI b / II試験において、Faslodexと組み合わせて評価される。 G1セラピュ―ティクスは米国のバイオ医薬品企業。臨床ステ―ジで、がん治療の新薬や治療法の発見・開発に従事する。細胞肺がんの治療用サイクリン依存性キナ―ゼ(CDK)4/6阻害薬と、乳がん治療用の経口タイプCDK4/6阻害薬やエストロゲン受容体ディグレ―ダ―などの新薬を開発する。本社所在地はノ―スカロライナ州リサ―チ・トライアングル・パ―ク。 G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the discovery, development and delivery of next generation therapies that improve the lives of those affected by cancer, including the Company's first commercial product, COSELA™ (trilaciclib). G1 has a deep clinical pipeline evaluating targeted cancer therapies in a variety of solid tumors, including colorectal, breast, lung, and bladder cancers. G1 Therapeutics is based in Research Triangle Park, N.C. |
| 本社所在地 | 79 T.W. Alexander Drive 4501 Research Commons Suite 100 Research Triangle Park NC 27709 USA |
| 代表者氏名 | Seth A. Rudnick Seth A. Rudnick |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 919-213-9835 |
| 設立年月日 | 39569 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2017年 |
| 従業員数 | － |
| url | www.g1therapeutics.com |
| nasdaq_url | https://www.nasdaq.com/symbol/gthx |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -75.46400 |
| 終値（lastsale） | 43.93 |
| 時価総額（marketcap） | 1467461222.55 |
| 時価総額 | 時価総額（百万ドル） 1688.8 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 1500.573 |
| 当期純利益 | 当期純利益（百万ドル） -73.86000 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 G1 Therapeutics Inc revenues was not reported. Net loss applicable to common stockholders increased 28% to $41.3M. Higher net loss reflects Research_Development - Balancing value increase of 40% to $33.3M (expense) General and Administrative - Balancing increase of 100% to $5.4M (expense) Stock-based Compensation in R&D increase from $1M to $2.4M (expense). |
GTHXのテクニカル分析
GTHXのニュース
Was anything positive for G1 Therapeutics Inc. (GTHX) stock last session? 2022/12/13 15:00:00 US Post News
G1 Therapeutics Inc. (NASDAQ:GTHX) closed Monday at $5.98 per share, up from $5.88 a day earlier. While G1 Therapeutics Inc. has overperformed by 1.70%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, GTHX fell by -43.05%, with highs and lows ranging from $17.49 to $3.84, whereas […]
G1 Therapeutics drug shows promise in initial data from phase 2 breast cancer trial 2022/12/08 12:26:52 Seeking Alpha
G1 Therapeutics (GTHX) said initial data from a phase 2 mechanism of action ((MOA)) trial showed favorable alterations in the tumor microenvironment from a single dose…
G1 Therapeutics Announces Inducement Grants Under Nasdaq 2022/12/02 04:41:00 businessfortnight.com
RESEARCH TRIANGLE PARK, N.C., Dec. 01, 2022 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for 14,400 […] The post G1 Therapeutics Announces Inducement Grants Under Nasdaq appeared first on Businessfortnight .
G1 Therapeutics raises $50M; millions more possible 2022/11/30 01:36:34 WRAL TechWire
(WRAL TechWire)
A closer look at G1 Therapeutics Inc. (GTHX) is warranted 2022/11/29 15:32:00 US Post News
A share of G1 Therapeutics Inc. (NASDAQ:GTHX) closed at $5.84 per share on Monday, down from $6.35 day before. While G1 Therapeutics Inc. has underperformed by -8.03%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, GTHX fell by -55.08%, with highs and lows ranging from $17.49 […]
G1 Therapeutics, Inc. (GTHX) Q2 2022 Earnings Call Transcript 2022/08/04 08:30:27 The Motley Fool
GTHX earnings call for the period ending June 30, 2022.
G1 Therapeutics, Inc. (GTHX) CEO Jack Bailey on Q1 2022 Results - Earnings Call Transcript 2022/08/03 18:32:02 Seeking Alpha
Symbotic Inc. (SYM) Q3 2022 Earnings Conference Call August 01, 2022, 05:00 PM ET Company Participants Will Roberts - Head-Corporate Communications Jack Bailey - CEO Jen Moses - CFO Andrew…
G1 Therapeutics PT Raised to $35 at Roth Capital 2022/08/03 16:04:05 Investing.com
https://www.investing.com/news/pro/g1-therapeutics-pt-raised-to-35-at-roth-capital-432SI-2862201
G1 Therapeutics: Q2 Earnings Insights 2022/08/03 11:36:41 Benzinga
G1 Therapeutics (NASDAQ: GTHX ) reported its Q2 earnings results on Wednesday, August 3, 2022 at 06:30 AM. Here''s what investors need to know about the announcement. Earnings G1 Therapeutics beat estimated earnings by 9.8%, reporting an EPS of $-0.92 versus … Full story available on Benzinga.com
G1 Therapeutics GAAP EPS of -$0.92 beats by $0.10, revenue of $10.57M beats by $1.7M 2022/08/03 10:34:08 Seeking Alpha
G1 Therapeutics press release (GTHX): Q2 GAAP EPS of -$0.92 beats by $0.10.Revenue of $10.57M (+60.2% Y/Y) beats by $1.7M.Achieved $8.7 Million in Net COSELA Revenue: G1…
G1 Therapeutics Inc. (NASDAQ:GTHX) Is Up 15.40% Over The Past 30 Days: Is There Trouble Ahead? 2022/07/02 18:00:00 Marketing Sentinel
In last trading session, G1 Therapeutics Inc. (NASDAQ:GTHX) saw 0.63 million shares changing hands with its beta currently measuring 1.85. Company’s recent per share price level of $5.17 trading at $0.23 or 4.66% at ring of the bell on the day assigns it a market valuation of $211.19M. That closing price of GTHX’s stock is … G1 Therapeutics Inc. (NASDAQ:GTHX) Is Up 15.40% Over The Past 30 Days: Is There Trouble Ahead? Read More »
Got $500? 3 Absurdly Cheap Healthcare Stocks That Are Set to Skyrocket 2022/07/01 20:45:00 The Motley Fool
Here''s why these Fool.com contributors are bullish on Adaptimmune Therapeutics, G1 Therapeutics, and Axsome Therapeutics.
G1 Therapeutics Inc. (NASDAQ: GTHX) Could Soon Experience A Sharp Increase In Its Share Price. 2022/06/01 15:00:00 Marketing Sentinel
In the last trading session, 1.87 million shares of the G1 Therapeutics Inc. (NASDAQ:GTHX) were traded, and its beta was 2.03. Most recently the company’s share price was $4.86, and it changed around -$0.43 or -8.13% from the last close, which brings the market valuation of the company to $185.94M. GTHX currently trades at a … G1 Therapeutics Inc. (NASDAQ: GTHX) Could Soon Experience A Sharp Increase In Its Share Price. Read More »
G1 Therapeutics (GTHX) Investor Presentation - Slideshow 2022/05/24 18:57:09 Seeking Alpha
The following slide deck was published by G1 Therapeutics, Inc.
Metastatic Breast Cancer Pipeline Report: Emerging Therapies and Treatment Outlook | DelveInsight 2022/05/24 17:00:00 Benzinga
New York, USAMetastatic Breast Cancer Pipeline Report: Emerging Therapies and Treatment Outlook | De, May 24, 2022 (GLOBE NEWSWIRE) -- Metastatic Breast Cancer Pipeline Report: Emerging Therapies and Treatment Outlook | DelveInsight Metastatic Breast Cancer Pipeline involves 120+ key companies continuously working towards developing 120+ Metastatic Breast Cancer treatment therapies, as per DelveInsight DelveInsight''s '' Metastatic Breast Cancer Pipeline Insight 2022 '' report provides comprehensive global coverage of available, marketed, and pipeline Metastatic Breast Cancer therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Metastatic Breast Cancer pipeline domain. Key Takeaways from the Metastatic Breast Cancer Pipeline Report DelveInsight''s Metastatic Breast Cancer Pipeline report depicts a robust space with 120+ active players working to develop 120+ pipeline therapies for Metastatic Breast Cancer treatment.